RedHill Biopharma has been granted a patent for WX-671, which can be used to treat or prevent diseases caused by coronavirus infection. The method involves administering an effective amount of WX-671 to individuals in need of treatment. GlobalData’s report on RedHill Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on RedHill Biopharma, Human telomerase RT biomarker was a key innovation area identified from patents. RedHill Biopharma's grant share as of February 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of coronavirus infection using wx-671 composition
A recently granted patent (Publication Number: US11918560B2) discloses a method for treating coronavirus infections by administering a composition containing WX-671, a serine protease inhibitor. The method involves administering an effective amount of WX-671, either in its free base form or hydrogen sulfate salt form, along with a pharmaceutically-acceptable carrier material in a unit dosage suitable for oral administration. The dosage form can be a solid dosage form, such as a capsule, with specific dosing regimens outlined for different variants of coronavirus.
Furthermore, the patent also covers the treatment of coronavirus infections mediated by a trypsin-like serine protease, specifically type II transmembrane serine proteases (TTSP), in a cell or tissue system. The method involves administering WX-671, preferably in its hydrogen sulfate salt form, along with a carrier material in a unit dosage form suitable for oral administration. This patent provides a detailed method for treating coronavirus infections by targeting specific proteases involved in the infection process, potentially offering a new avenue for therapeutic intervention in combating the virus.
To know more about GlobalData’s detailed insights on RedHill Biopharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
